Williane Fernanda Siqueira
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Williane Fernanda Siqueira has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
Daniella Castanheira Bartholomeu
Departamento de Parasitologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte MG, Brazil
5 shared publicationsLilian Lacerda Bueno
Programa de Pós-graduação em Ciências da Saúde: Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte MG, Brazil; Departamento de Parasitologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte MG, Brazil
5 shared publications- Ricardo Toshio Fujiwara
Laboratory of Immunobiology and Parasite Control, Institute of Biological Sciences, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
5 shared publications Mariana Santos Cardoso
Departamento de Parasitologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte MG, Brazil
4 shared publicationsAmanda S. Machado
Programa de Pós-Graduação em Ciências da Saúde: Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, 30130-100, Minas Gerais, Brazil
3 shared publications- Ana Laura Grossi de Oliveira
Programa de Pós‐Graduação em Ciências da Saúde: Infectologia e Medicina Tropical Universidade Federal de Minas Gerais Belo Horizonte Minas Gerais Brazil
3 shared publications
Latest Publications
- 18 June 2024
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 110 (1) , 116405
IgG seroprevalence of Toxoplasma gondii and Leishmania infantum in leprosy patients: Implications for screening and management of co-infections
- 18 June 2024
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 110 (1) , 116405
IgG seroprevalence of Toxoplasma gondii and Leishmania infantum in leprosy patients: Implications for screening and management of co-infections
- 4 January 2023
- Published by Elsevier in Acta Tropica
- Vol. 239, 106827
Serodiagnosis of leishmaniasis in asymptomatic and symptomatic dogs by use of the recombinant dynamin-1-like protein from Leishmania infantum: A preliminary study
- 4 January 2023
- Published by Elsevier in Acta Tropica
- Vol. 239, 106827
Serodiagnosis of leishmaniasis in asymptomatic and symptomatic dogs by use of the recombinant dynamin-1-like protein from Leishmania infantum: A preliminary study
- Open Access
- 17 September 2021
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 15 (9) , e0009759
The increased presence of repetitive motifs in the KDDR-plus recombinant protein, a kinesin-derived antigen from Leishmania infantum, improves the diagnostic performance of serological tests for human and canine visceral leishmaniasis
Visceral leishmaniasis (VL) is caused by protozoa belonging to theLeishmania donovanicomplex and is considered the most serious and fatal form among the different types of leishmaniasis, if not early diagnosed and treated. Among the measures of disease control stand out the management of infected dogs and the early diagnosis and appropriate treatment of human cases. Several antigens have been characterized for use in the VL diagnosis, among them are the recombinant kinesin-derived antigens fromL.infantum, as rK39 and rKDDR. The main difference between these antigens is the size of the non-repetitive kinesin region and the number of repetitions of the 39 amino acid degenerate motif (6.5 and 8.5 repeats in rK39 and rKDDR, respectively). This repetitive region has a high antigenicity score. To evaluate the effect of increasing the number of repeats on diagnostic performance, we designed the rKDDR-plus antigen, containing 15.3 repeats of the 39 amino acid degenerate motif, besides the absence of the non-repetitive portion fromL.infantumkinesin. Its performance was evaluated by enzyme-linked immunosorbent assay (ELISA) and rapid immunochromatographic test (ICT), and compared with the kinesin-derived antigens (rKDDR and rK39). In ELISA with human sera, all recombinant antigens had a sensitivity of 98%, whereas the specificity for rKDDR-plus, rKDDR and rK39 was 100%, 96% and 71%, respectively. When evaluated canine sera, the ELISA sensitivity was 97% for all antigens, and the specificity for rKDDR-plus, rKDDR and rK39 was 98%, 91% and 83%, respectively. Evaluation of the ICT/rKDDR-plus, using human sera, showed greater diagnostic sensitivity (90%) and specificity (100%), when compared to the IT LEISH (79% and 98%, respectively), which is based on the rK39 antigen. These results suggest that the increased presence of repetitive motifs in the rKDDR-plus protein improves the diagnostic performance of serological tests by increasing the specificity and accuracy of the diagnosis.
- 17 September 2021
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 15 (9) , e0009759
Open AccessThe increased presence of repetitive motifs in the KDDR-plus recombinant protein, a kinesin-derived antigen from Leishmania infantum, improves the diagnostic performance of serological tests for human and canine visceral leishmaniasis
Visceral leishmaniasis (VL) is caused by protozoa belonging to theLeishmania donovanicomplex and is considered the most serious and fatal form among the different types of leishmaniasis, if not early diagnosed and treated. Among the measures of disease control stand out the management of infected dogs and the early diagnosis and appropriate treatment of human cases. Several antigens have been characterized for use in the VL diagnosis, among them are the recombinant kinesin-derived antigens fromL.infantum, as rK39 and rKDDR. The main difference between these antigens is the size of the non-repetitive kinesin region and the number of repetitions of the 39 amino acid degenerate motif (6.5 and 8.5 repeats in rK39 and rKDDR, respectively). This repetitive region has a high antigenicity score. To evaluate the effect of increasing the number of repeats on diagnostic performance, we designed the rKDDR-plus antigen, containing 15.3 repeats of the 39 amino acid degenerate motif, besides the absence of the non-repetitive portion fromL.infantumkinesin. Its performance was evaluated by enzyme-linked immunosorbent assay (ELISA) and rapid immunochromatographic test (ICT), and compared with the kinesin-derived antigens (rKDDR and rK39). In ELISA with human sera, all recombinant antigens had a sensitivity of 98%, whereas the specificity for rKDDR-plus, rKDDR and rK39 was 100%, 96% and 71%, respectively. When evaluated canine sera, the ELISA sensitivity was 97% for all antigens, and the specificity for rKDDR-plus, rKDDR and rK39 was 98%, 91% and 83%, respectively. Evaluation of the ICT/rKDDR-plus, using human sera, showed greater diagnostic sensitivity (90%) and specificity (100%), when compared to the IT LEISH (79% and 98%, respectively), which is based on the rK39 antigen. These results suggest that the increased presence of repetitive motifs in the rKDDR-plus protein improves the diagnostic performance of serological tests by increasing the specificity and accuracy of the diagnosis.
- 1 February 2021
- Published by Elsevier in Microbial Pathogenesis
- Vol. 151, 104745
Leishmania eukaryotic elongation Factor-1 beta protein is immunogenic and induces parasitological protection in mice against Leishmania infantum infection
- 1 February 2021
- Published by Elsevier in Microbial Pathogenesis
- Vol. 151, 104745
Leishmania eukaryotic elongation Factor-1 beta protein is immunogenic and induces parasitological protection in mice against Leishmania infantum infection
- Top Cited PapersOpen Access
- 24 September 2020
- Published by MDPI AG in Biosensors
- Vol. 10 (10) , 133
Point of Care Diagnostics in Resource-Limited Settings: A Review of the Present and Future of PoC in Its Most Needed Environment
Point of care (PoC) diagnostics are at the focus of government initiatives, NGOs and fundamental research alike. In high-income countries, the hope is to streamline the diagnostic procedure, minimize costs and make healthcare processes more efficient and faster, which, in some cases, can be more a matter of convenience than necessity. However, in resource-limited settings such as low-income countries, PoC-diagnostics might be the only viable route, when the next laboratory is hours away. Therefore, it is especially important to focus research into novel diagnostics for these countries in order to alleviate suffering due to infectious disease. In this review, the current research describing the use of PoC diagnostics in resource-limited settings and the potential bottlenecks along the value chain that prevent their widespread application is summarized. To this end, we will look at literature that investigates different parts of the value chain, such as fundamental research and market economics, as well as actual use at healthcare providers. We aim to create an integrated picture of potential PoC barriers, from the first start of research at universities to patient treatment in the field. Results from the literature will be discussed with the aim to bring all important steps and aspects together in order to illustrate how effectively PoC is being used in low-income countries. In addition, we discuss what is needed to improve the situation further, in order to use this technology to its fullest advantage and avoid “leaks in the pipeline”, when a promising device fails to take the next step of the valorization pathway and is abandoned.
- 24 September 2020
- Published by MDPI AG in Biosensors
- Vol. 10 (10) , 133
Top Cited PapersOpen AccessPoint of Care Diagnostics in Resource-Limited Settings: A Review of the Present and Future of PoC in Its Most Needed Environment
Point of care (PoC) diagnostics are at the focus of government initiatives, NGOs and fundamental research alike. In high-income countries, the hope is to streamline the diagnostic procedure, minimize costs and make healthcare processes more efficient and faster, which, in some cases, can be more a matter of convenience than necessity. However, in resource-limited settings such as low-income countries, PoC-diagnostics might be the only viable route, when the next laboratory is hours away. Therefore, it is especially important to focus research into novel diagnostics for these countries in order to alleviate suffering due to infectious disease. In this review, the current research describing the use of PoC diagnostics in resource-limited settings and the potential bottlenecks along the value chain that prevent their widespread application is summarized. To this end, we will look at literature that investigates different parts of the value chain, such as fundamental research and market economics, as well as actual use at healthcare providers. We aim to create an integrated picture of potential PoC barriers, from the first start of research at universities to patient treatment in the field. Results from the literature will be discussed with the aim to bring all important steps and aspects together in order to illustrate how effectively PoC is being used in low-income countries. In addition, we discuss what is needed to improve the situation further, in order to use this technology to its fullest advantage and avoid “leaks in the pipeline”, when a promising device fails to take the next step of the valorization pathway and is abandoned.
- 1 May 2020
- Published by Stricto Sensu Editora
- p. 64-80
DESAFIOS E AVANÇOS NOS DIAGNÓSTICOS SOROLÓGICO E MOLECULAR DA HANSENÍASE
- 1 May 2020
- Published by Stricto Sensu Editora
- p. 64-80
DESAFIOS E AVANÇOS NOS DIAGNÓSTICOS SOROLÓGICO E MOLECULAR DA HANSENÍASE
- 1 May 2020
- Published by Stricto Sensu Editora
- p. 288-305
LEISHMANIOSE VISCERAL: CONTRIBUIÇÕES HISTÓRICAS E AVANÇOS NO DIAGNÓSTICO PARA O CONTROLE DA DOENÇA
- 1 May 2020
- Published by Stricto Sensu Editora
- p. 288-305
LEISHMANIOSE VISCERAL: CONTRIBUIÇÕES HISTÓRICAS E AVANÇOS NO DIAGNÓSTICO PARA O CONTROLE DA DOENÇA
- 1 December 2019
- Published by Elsevier in Microbial Pathogenesis
- Vol. 137, 103783
Recombinant Leishmania eukaryotic elongation factor-1 beta protein: A potential diagnostic antigen to detect tegumentary and visceral leishmaniasis in dogs and humans
- 1 December 2019
- Published by Elsevier in Microbial Pathogenesis
- Vol. 137, 103783
Recombinant Leishmania eukaryotic elongation factor-1 beta protein: A potential diagnostic antigen to detect tegumentary and visceral leishmaniasis in dogs and humans
- 1 May 2019
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 57 (5)
Development of a Multiplexed Assay for Detection of Leishmania donovani and Leishmania infantum Protein Biomarkers in Urine Samples of Patients with Visceral Leishmaniasis
Visceral leishmaniasis (VL) is a serious and fatal disease caused by the parasites Leishmania infantum and Leishmania donovani. The gold standard diagnostic test for VL is the demonstration of parasites or their DNA from spleen, lymph node or bone marrow aspirates. Serological tests exist but cannot distinguish active VL from either prior exposure to the parasites or subsequent to disease treatment. Using mass spectroscopy, we have previously identified three L. infantum protein biomarkers (Li-isd1, Li-txn1, and Li-ntf2) in urine of VL patients and developed a sensitive and specific urine-based antigen detection assay for diagnosis of VL that occurs in Brazil (where VL is caused by L. infantum). However, unpublished observations from our laboratory showed that these biomarkers were detected in only 55-60% of VL patients from India and Kenya, where the disease is caused by L. donovani. Here, we report the discovery and characterization of two new biomarkers of L. donovani (Ld-mao1 and Ld-ppi1) present in the urine of VL patients from these two countries. Capture ELISAs using specific rabbit IgG and chicken IgY were developed and the assays had sensitivities of 44.4% and 28.8% to detect Ld-mao1 and Ld-ppi1 respectively. In contrast, a multiplexed assay designed to simultaneously detect all five leishmanial biomarkers markedly increased the assay sensitivity to 82.2%. These results validate the utility of leishmanial protein biomarkers found in urine of VL patients as powerful tools for the development of an accurate diagnostic tests for this disease.
- 1 May 2019
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 57 (5)
Development of a Multiplexed Assay for Detection of Leishmania donovani and Leishmania infantum Protein Biomarkers in Urine Samples of Patients with Visceral Leishmaniasis
Visceral leishmaniasis (VL) is a serious and fatal disease caused by the parasites Leishmania infantum and Leishmania donovani. The gold standard diagnostic test for VL is the demonstration of parasites or their DNA from spleen, lymph node or bone marrow aspirates. Serological tests exist but cannot distinguish active VL from either prior exposure to the parasites or subsequent to disease treatment. Using mass spectroscopy, we have previously identified three L. infantum protein biomarkers (Li-isd1, Li-txn1, and Li-ntf2) in urine of VL patients and developed a sensitive and specific urine-based antigen detection assay for diagnosis of VL that occurs in Brazil (where VL is caused by L. infantum). However, unpublished observations from our laboratory showed that these biomarkers were detected in only 55-60% of VL patients from India and Kenya, where the disease is caused by L. donovani. Here, we report the discovery and characterization of two new biomarkers of L. donovani (Ld-mao1 and Ld-ppi1) present in the urine of VL patients from these two countries. Capture ELISAs using specific rabbit IgG and chicken IgY were developed and the assays had sensitivities of 44.4% and 28.8% to detect Ld-mao1 and Ld-ppi1 respectively. In contrast, a multiplexed assay designed to simultaneously detect all five leishmanial biomarkers markedly increased the assay sensitivity to 82.2%. These results validate the utility of leishmanial protein biomarkers found in urine of VL patients as powerful tools for the development of an accurate diagnostic tests for this disease.